CLINICAL EFFICACY OF THE VARIOUS DRUGS USED IN THE TREATMENT OF GONORRHOEA
AbstractBackground: Gonorrhoea is a purulent inflammation of mucus membrane of the genital tract andis a highly contagious sexually transmitted disease (STD) caused by the bacterium Neisseriagonorrhoae. Both men and women can be infected through a variety of sexual contact behavioursincluding vaginal, anal or oral intercourses. This comparative study was carried out in New GulailPolyclinic Jeddah, KSA from Jan 2003 to March 2004 to find the clinical efficacy ofciprofloxacin, ceftriaxone and spectinomycin, the three commonly used drugs, in the treatment ofgonorrhoea. Methods: A total number of 300 patients suffering from gonorrhoea were included inthis study. They were randomly divided into 3 groups of 100 patients each. Group-A patients weregiven Tablet Ciprofloxacin 500 mg, Group-B patients Injection Ceftriaxone 500 mg, and Group-Cpatients were put on Injection Spectinomycin 2 gm, all in stat dosage. On the 5th day following thetreatment, all patients were re-examined and their clinical and laboratory findings were recordedand analysed. Results: On the 5th day following treatment the Group-A (n=100) showed 9 (9%)partial response and 11 (11%) cases showed no response to Ciprofloxacin. In the Group-B(n=100), 4 (4%) patients showed partial response and 6 (6%) patients showed no response toCeftriaxone. In Group-C, out of 100 patients, 4 (4%) cases reported with partial response and 2(2%) patients showed no response to Spectinomycin. The efficacy of these anti-microbial agentswas the same in both the genders. Conclusion: Anti-microbial susceptibility of N. gonorrrhoeaeto various antibiotics is gradually decreasing. In order to ensure full cure, all gonorrhoea patientsshould be followed-up after a single dosage of any antibiotic. Further research should continue fornewer, effective, and preferably oral medication for the treatment of gonorrhoea.Keywords: Neisseria gonorrhoeae, sexually transmitted infection, STD, Sexually TransmittedDisease, Gonorrhoea
Britigan BE, Cohen MS, Sparling PF. Gonococcal infection;a model
of molecular pathogenesis. N Engl J Med 1985;312:683–94.
Woods CR. Gonococcal infections in neonates and young children.
Semin Pediatr Infect Dis 2005;16;258–70.
Barlow D, Phillips I. Gonorrhoea in women–diagnostic, clinical and
therapeutic aspects. Lancet, 1978;I(8067):761–4.
Johnson RA. Diagnosis and treatment of common sexually
transmitted diseases in women. Clin Cornerstone 2000;3(1):1–11.
Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson
GM, et al. Sexual behaviour, STDS & risks of prostatic cancer. Br J
Knapp JS, Wongba C, Limpakarnjanarat K, Young NL, Parekh MC,
Neal SW, et al. Antimicrobial susceptibilities of strains of N.
Gonorrhoeae in Bangkok, Thailand 1994-1995. Sex Transm Dis
Johnson SR, Morse SA. Antibiotic resistance in N. Gonorrhoeae:
Genetics and mechanisms of resistance. Sex Transm Dis
Zheng HP, Cao WL, Wu XZ, Yang LG. Antimicrobial
susceptibilities of strains of N.Gonorrhoeae srains isolated in
Guangzhou, China.1996–2001. Sex Transm Infect
Rahman M, Sultan Z, Monira S, Alam A, Nessa K, Islam S,
Antimicrobial susceptibility of N.Gonorrhoeae isolated in
Bangladesh (1997 to 1999), rapid shift to fluoroquinolone resistance.
J Clin Microbiol 2002;40(6);2037–40.
Jephcott AE. Microbiological diagnosis of gonorrhoea. Genitourin
Su X, Hutapea N, Tapsall JW, Lind I. Plasmid-mediated resistance
of Neisseria gonorrhoeae strains isolated from female sex workers
in North Sumatra, Indonesia, 1996. Sex Transm Dis
National institute of Allergy and Infectious Diseases; National
institutes of Health, Department of Health and Human Services
(2001-07-20). ‘Workshop Summary; Scientific Evidence on
Condom Effectiveness for Sexually Transmitted Disease (STD)
Prevention” Hyatt Dulles Airport, Herndon, Virginia. pp 14.
Annual report of the Australian Gonococcal Surveillance Program.
, Commun Dis Intell 1999;23(7):193-7.
Herida M, Srdnaoni P, Goulet V. Gonorrhoea Surveillance System
in France: 1986–2000. Sex Transm Dis 2004;31(4):209–14.
Bhuiya BU, Rahman M, Miah MRA. Nahar S, Islam N, Ahmed M,
et al. Antimicrobial Susceptibilities and Plasmid Contents of
Neisseria gonorrhoeae Isolates from Commercial Sex Workers in
Dhaka, Bangladesh: Emergence of High-Level Resistance to
Ciprofloxacin. J Clin Microbiol 1999;37(4):1130–6.
Centers for Disease Control & Prevention. “Gonorrhoea among
men who have sex with men: 1993–96. JAMA 1997;278: 1228–9.
Ison CA, Martin IM. Gonorrhoea in London: Usefulness of First
Line Therapies. Sex Transm Inf 2002;78:106–9.
Heffernan H, Brokenshire M, Woodhouse R, MacCarthy A,
Blackmore T. Antimicrobial susceptibility among N. gonorrhoeae in
New Zealand in 2002. NZ Med J 2004;117(1191):U817.
Ng LK, Martin I, Lau A. Trends of chromosomally mediated
antimicrobial resistance in N. gonorrhoeae in Canada. Sex Transm
Collier AC, Judson FN, Murphy VL, Leach LA, Root CJ,
Handsfield HH. Comparative study on Ceftriaxone and
Spectinomycin in the treatment of uncomplicated gonorrhoea in
women. Am J Med 1984;77 (4c):68–72.
Easmon CS, Forster GE,Walker GD, Ison CA, Harris JR, Munday
PE. Spectinomycin as initial treatment for gonorrhoea. BMJ
Ye S, Su X, Wang Q, Yin Y, Dai X, Sun H. Surveillance of
antibiotic resistance of N.gonorrhoeae isolates in China, 1993–98.
Sex Transm Dis 2002;29:242–5.
Echolas PM, Hyed A, Okeefe BJ, Schacht P. Single dose
Ciprofloxacin for the treatment of uncomplicated gonorrhoea. Sex
Transm Dis 1994;21(6)345–52.
Nissinen A, Jarvinen H, Jahkola M, Limatainen O. Antimicrobial
resistance in N. gonorrhoeae in Finland, 1976–5. Sex Transm Dis
Stapinski A, Gede K. Treatment of gonorrhoea with Spectinomycin.
Pregl Dermatol 1983;70(2):115–20.